Rochester, MN – June 19, 2025 – SIME Diagnostics is proud to announce that [...]
SIME Diagnostics, a UK-based medical technology company today announced the completion of a clinical study [...]
SIME Diagnostics has announced the publication of a clinical study in Diagnostics Journal, evaluating a [...]
The FAST 2 (Fourier-transform Infrared Spectroscopy guided Surfactant Therapy) trial begins in 4 Danish University [...]
The point-of-care device, which predicts severe lung disease in the ICU and NICU, has been CE [...]
Morten Henneveld, a life science executive with decades of commercial and operations experience, joins SIME [...]
Global neonatal key opinion leaders conclude that prediction of CLD at birth may prevent or [...]
First of its kind diagnostic for measuring surfactant in multifactorial Acute Respiratory Distress Syndrome (ARDS) [...]
LONDON, Nov. 11, 2020 /PRNewswire/ — SIME Clinical AI today announced that the European Patent Office intends [...]
A recent peer reviewed letter to editor by SIME has been published in Critical Care [...]
